CD19 and CD22 targeted prime CAR-T cells
PBC025
Phase 2 mab active
Quick answer
CD19 and CD22 targeted prime CAR-T cells for B-ALL is a Phase 2 program (mab) at PRECISION BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- PRECISION BIOSCIENCES INC
- Indication
- B-ALL
- Phase
- Phase 2
- Modality
- mab
- Status
- active